XOMA Royalty Corp.

NASDAQ:XOMA

Biotechnology

Healthcare
$40.17 +0.44%

+$0.19 today

Market cap
$503.77M
Beta
0.87
P/E (TTM)
15.8
EPS (TTM)
$2.65
52W Low $22.29High $42.81

Volume 4.22M

Average 0.21M

XOMA Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

XOMA Royalty Corp.NASDAQ: XOMA

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 4.6% from a year ago

Cash & equivalents stood at $94.46M at the end of Q1 FY2026, up 4.6% from a year earlier and up 13.9% from the prior quarter. Over 3 fiscal years it compounded at +12.8% a year.

Context

  • Cash & equivalents amounted to 34.7% of total assets at the end of Q1 FY2026, down 7.7 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +4.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$94.46M+13.9% QoQ
Last fiscal yearDec 2025
$82.91M-18.4% YoY
Year agoMar 2025
$90.27M+4.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.6%——
1 year-18.4%——
3-year CAGR+12.8%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
82.91M USD
Year-over-year change
-18.4%
4-year CAGR
-2.9%

Cash & Equivalents vs competitors

How XOMA compares with its peers on the latest reported figures

  • XOMA's Mar 2026 cash & equivalents of $94.46M is the 4th highest of the 10 companies compared; the peer median is $49.61M.
  • Its year-over-year change of +4.6% is the 7th highest of 10, against a peer median of +41.4%.
  • Cash & equivalents amounts to 34.7% of total assets for XOMA, versus a peer median of 24.8%.
XOMA Competitors Peer median
Cash & Equivalents for XOMA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SLDBSolid Biosciences Inc.Mar 2026$297.74M +41.4%-27.2%70.4%
BNTCBenitec Biopharma Inc.Mar 2026$184.76M +78.4%+188.7%98.8%
AUTLAutolus Therapeutics plcMar 2026$130.93M +36.7%-35.2%24.8%
XOMAXOMA Royalty Corp.Mar 2026$94.46M +4.6%+12.8%34.7%
AURAAura Biosciences, Inc.Mar 2026$84.79M +121.8%-21.2%61.6%
RCKTRocket Pharmaceuticals, Inc.Mar 2026$49.61M -0.4%-18.0%17.4%
QSIQuantum-Si incorporatedMar 2026$36.2M -2.9%-36.5%17.0%
GALTGalectin Therapeutics Inc.Mar 2026$14.11M +89.9%-1.6%89.5%
DSGNDesign Therapeutics, Inc.Mar 2026$12.77M -6.6%-14.0%5.5%
DMACDiaMedica Therapeutics Inc.Mar 2026$4.87M +88.0%+49.0%9.2%
Peer median (excluding XOMA) $49.61M+41.4%-18.0%24.8%

Competitors are the stored peer set for XOMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents93.33M57.83M153.29M101.65M82.91M
Short-term Investments774K335K161K3.53M382K
Net Receivables209K2.37M15.22M17.02M4.9M
Inventory00000
Other Current Assets2.05M725K643K1.33M29.46M
Total Current Assets96.97M61.25M169.31M125.6M117.26M
Property, Plant & Equipment (Net)213K36K403K351K277K
Goodwill00000
Intangible Assets015.15M025.91M44.76M
Long-term Investments063.68M64.05M64.34M106.38M
Tax Assets0(63.68M)000
Other Non-current Assets69.38M63.94M533K5.08M4.03M
Total Non-current Assets69.59M79.13M64.99M95.67M155.44M
Total Assets166.56M140.38M234.3M221.28M272.7M
Account Payables1.07M524K653K1.05M2.21M
Short-term Debt005.54M11.39M12.53M
Tax Payables91K00280K0
Deferred Revenue1.64M1.9M2.11M1.36M1.27M
Other Current Liabilities8.13M2.35M9.78M3M9.89M
Total Current Liabilities12.97M6.82M19.5M24.37M34.82M
Long-term Debt00118.52M106.88M116.57M
Deferred Tax Liabilities0000103K
Deferred Revenue (Non-current)11.69M9.55M7.23M4.41M3.19M
Other Non-current Liabilities0003.21M14.06M
Total Non-current Liabilities11.72M9.55M126.08M114.98M133.92M
Total Liabilities24.69M16.37M145.58M139.36M168.74M
Common Stock85K86K86K90K89K
Retained Earnings(1.17B)(1.18B)(1.22B)(1.24B)(1.22B)
Accumulated OCI00073K53K
Other Stockholders Equity00000
Minority Interest00000
Total Equity141.88M124.01M88.72M81.92M103.96M
Total Debt229K34K124.45M119.2M131.56M
Net Debt(93.1M)(57.79M)(28.84M)17.54M48.65M

XOMA Royalty Corp.

NASDAQ:XOMA

Intrinsic Alpha fair value

Locked

Current Price

$40.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.